ARCpoint Labs Franchise Review (2026): Costs, Fees, Revenue Potential

• Category: Health & Wellness
• Initial Investment (range): $165,700 to $310,420
• Franchise Fee: $7,500 disclosed minimum; the FDD also references higher franchise fee amounts for additional structures the disclosure does not clearly reconcile here
• Royalty: 7% of gross revenue, with a $350 monthly minimum
• Marketing / Ad Fee: 2% national marketing fund currently, which may increase to 3%; local advertising requirement shown as 3%
• Key additional recurring fees: technology fee of $300 per month; doctor referral fee up to $2 per requisition and/or injection; possible advertising cooperative fee of 1% to 3% if implemented
• Number of locations: 124 franchised locations in operation as of December 31, 2024; Item 20 also shows 124 franchised outlets at year-end 2024 and 4 affiliate-operated outlets
• Best Fit: manager-led or active oversight owner, not passive ownership

---

The estimated initial investment is $165,700 to $310,420 for a single territory. The disclosure also lists additional funds of $54,000 to $72,000, which suggests a meaningful working-capital cushion is expected.

Major cost drivers appear to include the franchise fee structure, equipment-related needs, and the operating setup required for a testing business. The disclosure also indicates the business is equipment-heavy and technology is significant to the model.

On balance, this reads as a mid-cost franchise based on the stated range. It is not a low-cost entry point, but it is also not presented as an unusually large capital requirement within franchise investing generally.

---

• Royalty fee: 7% of gross revenue per month, with a minimum of $350 per month
• National marketing fund: currently 2% of gross revenue per month; may increase to 3%
• Local advertising: 3% indicated
• Advertising cooperative / multi-area marketing: 1% to 3% of gross revenue if implemented in the market area
• Technology fee: $300 per month
• Doctor referral fee: up to $2 per requisition and/or injection
• Other possible fees: training fees, onsite assistance, transfer fee, audit-related charges, late fees, insufficient funds fee, collection costs, and legal costs

Overall, the recurring fee load is moderate but layered. The royalty is straightforward, while marketing, technology, and doctor referral charges can add to the effective burden depending on how the business operates.

---

Yes, the FDD includes Item 19 revenue data, but it is revenue data only, not profit.

The disclosed metric is 2024 Gross Revenues Minus Clinical Program Sales for franchised businesses open at least 12 months and reporting the required data.

Reported Item 19 figures

• Top 20% (19 businesses)
  • Average: $544,193
  • Median: $498,697
  • Range: $328,701 to $1,163,454
• Middle 60% (57 businesses)
  • Average: $154,694
  • Median: $148,191
  • Range: $59,494 to $297,660
• Bottom 20% (19 businesses)
  • Average: $29,551
  • Median: $25,694
  • Range: $234 to $57,469

What the numbers suggest

The spread is wide. The top segment’s average revenue is far above the middle and bottom segments, which indicates substantial unit-level variability. Even within segments, the ranges are broad, especially at the top.

The middle 60% is likely the most useful reference point for a typical screening discussion: average revenue of $154,694 and median revenue of $148,191. That said, the bottom 20% shows that some units generated very limited revenue, with the range starting at $234.

Important caveats from the disclosure:

• These figures are based on unaudited franchisee reports.
• The metric is gross revenue minus clinical program sales, not total revenue and not earnings.
• Of 115 franchised businesses open at least 12 months as of December 31, 2024, 20 were excluded because they did not report clinical program sales data for each of the 12 months in 2024.
• The disclosure also flags that the Item 19 presentation is based on non-U.S. operations, which may affect comparability for a buyer evaluating a specific market.

Revenue does not equal profit. From these figures alone, the FDD does not establish store-level profitability, owner income, or cash flow after labor, occupancy, equipment, referral fees, marketing, and other operating costs.

---

• B2B / B2C: Primarily B2B based on the disclosure’s audience inference, though the revenue definition also references onsite/online operations and services/products sold broadly
• Revenue pattern: Service-driven revenue, likely recurring to the extent client relationships repeat, but the disclosure does not clearly quantify recurring versus one-time revenue
• Operating characteristics: Requires direct day-to-day supervision by a trained owner or manager; technology appears significant; equipment needs appear meaningful; physician referral mechanics may be part of service delivery for many tests

This is not presented as a passive licensing model. The operating structure appears compliance- and process-oriented, with ongoing management requirements.

---

Advantages

• Item 19 includes segmented revenue data across 95 franchised businesses, giving a concrete view of revenue dispersion.
• The system had 124 franchised locations operating as of December 31, 2024.
• The franchise term is 10 years, which may matter for investors evaluating time horizon.
• The model allows a trained manager, not only the owner, to directly supervise day-to-day operations.

Considerations

• Startup cost is meaningful at $165,700 to $310,420, plus $54,000 to $72,000 in additional funds.
• Recurring fees are layered: royalty, national marketing, local advertising, technology, and potentially doctor referral and cooperative advertising fees.
• Revenue outcomes vary sharply across the disclosed segments.
• Territory is non-exclusive.
• One owner or a trained manager must directly supervise daily operations, which limits passive ownership.

---

This franchise may fit someone comfortable with an operationally involved service business, especially an owner who plans to oversee a manager or serve in an active supervisory role. It may also fit buyers who want Item 19 revenue data to frame downside and upside scenarios, while recognizing that the disclosed figures are not profit figures.

It likely does not fit someone seeking a passive investment, exclusive territorial protection, or a simple fee structure with few operational dependencies.

---

• The franchisor states it does not operate ARCpoint Labs businesses, so the disclosure does not provide franchisor-operated outlet performance as a reference point.
• Systemwide outlet count declined in 2024, with franchised outlets moving from 134 at the start of the year to 124 at year-end.
• The disclosure indicates litigation mentions.
• Certain defaults appear to be non-curable, including misrepresentation, failure to complete initial training, bankruptcy-related events, abandonment, unapproved transfers, and breach of confidentiality.
• Claims subject to arbitration are tied to Fulton County, Georgia, and Georgia law applies under the franchise agreement summary.

---

ARCpoint Labs presents a service-based model with a mid-range startup cost, a moderate but layered fee structure, and clear evidence of wide revenue variability across units. The main tradeoff is that buyers get actual revenue benchmarks in the FDD, but the model still appears operationally demanding, non-exclusive territorially, and far from passive.

---